LON:XEN - Xenetic Biosciences UK Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeGBX 4 - GBX 9.23
Average Volume539,436 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Xenetic Biosciences plc, formerly Lipoxen plc, is a holding company engaged in development of drug and vaccine delivery systems and products in fields of protein drugs, vaccines and oncology. The Company's technology platforms include PolyXen for extending efficacy and half life of biologic drugs; ImuXen for creating new vaccines and improving existing vaccines, and OncoHist for novel mode of action drugs for oncology therapies. It has drug and vaccine programs with three products in human clinical development, such as ErepoXen, which is a long-acting formulation for treatment of anaemia in both End Stage Renal Disease patients and for those undergoing chemotherapy; OncoHist, which is a recombinant human histone H1.3 molecule in Phase I clinical trials in Russia for refractory Acute Myeloid Leukaemia and Non Hodgkin's Lymphoma, and SuliXen, which is insulin for both treatment of diabetes and for central nervous system condition. On January 17, 2012, the Company acquired SymbioTec GmbH.

Receive XEN News and Ratings via Email

Sign-up to receive the latest news and ratings for XEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A



Sales & Book Value

Annual SalesN/A



OptionableNot Optionable

Xenetic Biosciences UK (LON:XEN) Frequently Asked Questions

What is Xenetic Biosciences UK's stock symbol?

Xenetic Biosciences UK trades on the London Stock Exchange (LON) under the ticker symbol "XEN."

Has Xenetic Biosciences UK been receiving favorable news coverage?

News headlines about XEN stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Xenetic Biosciences UK earned a coverage optimism score of 1.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of Xenetic Biosciences UK?

Shares of XEN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How can I contact Xenetic Biosciences UK?

Xenetic Biosciences UK's mailing address is Ste 230, 99 Hayden Ave, LONDON, 2421, United Kingdom. The company can be reached via phone at +44-20-30211500.

MarketBeat Community Rating for Xenetic Biosciences UK (LON XEN)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  67
MarketBeat's community ratings are surveys of what our community members think about Xenetic Biosciences UK and other stocks. Vote "Outperform" if you believe XEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel